Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2006-03-27
2009-06-23
Lewis, Patrick T (Department: 1623)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S123100, C536S124000
Reexamination Certificate
active
07550584
ABSTRACT:
The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.
REFERENCES:
patent: 4138479 (1979-02-01), Truscheit et al.
patent: 4739046 (1988-04-01), Di Luzio
patent: 4804545 (1989-02-01), Goering et al.
patent: 4897220 (1990-01-01), Trieselt et al.
patent: 5223491 (1993-06-01), Donzis
patent: 5397773 (1995-03-01), Donzis
patent: 5401727 (1995-03-01), Rorstad et al.
patent: 5519009 (1996-05-01), Donzis
patent: 5576015 (1996-11-01), Donzis
patent: 5622940 (1997-04-01), Ostroff
patent: 5702719 (1997-12-01), Donzis
patent: 5705184 (1998-01-01), Donzis
patent: 6117850 (2000-09-01), Patchen et al.
patent: 6214337 (2001-04-01), Hayen et al.
patent: 6242594 (2001-06-01), Kelly
patent: 6340703 (2002-01-01), Kelly
patent: 6423832 (2002-07-01), Seljelid
patent: 6497863 (2002-12-01), Wachter et al.
patent: 6497865 (2002-12-01), Griesbach et al.
patent: 6500410 (2002-12-01), Griesbach et al.
patent: 6534098 (2003-03-01), Muhlbauer
patent: 6858214 (2005-02-01), Kropf et al.
patent: 6875754 (2005-04-01), Griesbach et al.
patent: 6964775 (2005-11-01), Wachter et al.
patent: WO 91/07091 (1991-05-01), None
Babineau, Timothy J., et al., “Randomized Phase I/II Trial of a Macrophage-Specific Immunomodulator (PGG-Glucan) in High-Risk Surgical Patients,”Annals of Surgery, vol. 220, No. 5, pp. 601-609, 1994.
Czop, Joyce K. et al., “Isolation and Characterization of β-Glucan Receptors on Human Mononuclear Phagocytes,”J. Exp. Med., vol. 173, pp. 1511-1520, Jun. 1991.
Sherwood, E.R., et al., “Glucan Stimulates Production of Antitumor Cytolytic/Cytostatic Factor(s) by Macrophages”J. Biological Response Modifiers, vol. 5, pp. 504-526, 1986.
Sherwood, E.R., et al., “Enhancement of Interleukin-1 and Interleukin-2 Production by Soluble Glucan,”Int. J. Immunopharmac., vol. 9, No. 3, pp. 261-267, 1987.
Williams, D.L., et al., “Immunopharmacologic Modification of Experimental Viral Diseases by Glucan,”J. Immun. and Immunopharmac., vol. 5, No. 2, pp. 78-82, 185.
Williams, D.L., et al., “Protective Effect of Glucan in Experimentally Induced Candidiasis,”J. of the Reticuloendothelial, vol. 23, No. 6, pp. 479-490, Jun. 1978.
Ueno, Hiroiku, “Beta-1, 3-D-Glucan, its Immune Effect and its Clinical Use,”Japanese Journal Society Terminal Systemic Diseases, vol. 6, pp. 151-154, 2000.
Bahl Arun K.
Klein Elias
Vercellotti John R.
Vercellotti Sharon V.
DLA Piper (LLP) US
Immudyne, Inc.
Lewis Patrick T
LandOfFree
Methods of purifying beta glucans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of purifying beta glucans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of purifying beta glucans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4100099